Miflonide Breezhaler (Budesonide)

Budesonide, the active ingredient in Miflonide Breezhaler, is a glucocorticoid presented as an inhalation powder for inhalation use. It treats asthma and chronic obstructive pulmonary disease (COPD) in adults and children as prescribed, delivered via the Breezhaler device, providing consistent dose distribution to the lower airways.

GNH USA supplies Miflonide Breezhaler as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through its global network.

Budesonide, delivered via Miflonide Breezhaler, is used in the management of inflammatory airway diseases. - Asthma: reduces airway inflammation and improves symptom control. - Chronic obstructive pulmonary disease (COPD): decreases exacerbation frequency and enhances lung function. - Maintenance therapy for asthma: provides long‑term control of symptoms and reduces need for rescue medication.

Adverse reactions to budesonide inhalation may vary in frequency and severity.

Common Side Effects: - Hoarseness or voice change. - Throat irritation or cough. - Oral candidiasis (thrush). - Headache.

Serious or Rare Side Effects: - Adrenal suppression. - Pneumonia. - Paradoxical bronchospasm.

When prescribing Miflonide Breezhaler, clinicians should consider several safety measures. - Assess infection risk: evaluate for active respiratory infections before initiating therapy. - Monitor growth in children: periodic height and weight checks are recommended. - Use mouth rinse: advise patients to rinse and expectorate after inhalation to reduce oral candidiasis. - Avoid abrupt discontinuation: taper the dose when stopping long‑term therapy to prevent adrenal insufficiency. - Review concomitant immunosuppressants: adjust monitoring if used together. - Store at ambient temperature: keep in original packaging, protect from moisture and heat.

Budesonide may interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase systemic exposure. - Systemic glucocorticoids may heighten risk of adrenal suppression. - Live vaccines may have reduced efficacy.

Moderate Interactions (Monitor Closely): - Diuretics may increase risk of hypokalemia. - Moderate CYP3A4 inhibitors (e.g., azole antifungals) may modestly raise exposure.